Nissim, Sahar
Leshchiner, Ignaty
Mancias, Joseph D.
Greenblatt, Matthew B.
Maertens, Ophélia
Cassa, Christopher A.
Rosenfeld, Jill A.
Cox, Andrew G.
Hedgepeth, John
Wucherpfennig, Julia I.
Kim, Andrew J.
Henderson, Jake E.
Gonyo, Patrick
Brandt, Anthony http://orcid.org/0000-0002-1579-9666
Lorimer, Ellen
Unger, Bethany
Prokop, Jeremy W.
Heidel, Jerry R.
Wang, Xiao-Xu
Ukaegbu, Chinedu I.
Jennings, Benjamin C.
Paulo, Joao A. http://orcid.org/0000-0002-4291-413X
Gableske, Sebastian
Fierke, Carol A.
Getz, Gad
Sunyaev, Shamil R. http://orcid.org/0000-0001-5715-5677
Wade Harper, J.
Cichowski, Karen
Kimmelman, Alec C.
Houvras, Yariv
Syngal, Sapna
Williams, Carol
Goessling, Wolfram http://orcid.org/0000-0001-9972-1569
Article History
Received: 20 October 2017
Accepted: 1 July 2019
First Online: 12 August 2019
Competing interests
: A.C.K. has financial interests in Vescor Therapeutics, LLC. A.C.K. is an inventor on patents pertaining to Kras-regulated metabolic pathways, redox control pathways in pancreatic cancer, targeting GOT1 as a therapeutic approach and the autophagic control of iron metabolism. A.C.K. is on the SAB of Cornerstone/Rafael Pharmaceuticals. G.G. receives research funds from IBM and Pharmacyclics. W.G. receives patent royalties from FATE Therapeutics and is on the SAB of Camp4 Therapeutics.